title: Inhibitory effects of captopril on c-myc expression during left ventricular hypertrophy.
abstract: OBJECTIVE
  To study the molecular mechanism of captopril (Cap) on the inhibition of left ventricular hypertrophy (LVH), disclose the expression and distribution of c-myc in different cell types in left ventricle (LV) in spontaneously hypertensive rats (SHR).
  
  
  METHODS
  Cap 100 mg.kg-1.d-1 was given p.o. to SHR. Systolic blood pressure (SBP), left ventricular weight (LVW), and body weight (BW) were measured at 16-wk old. The level of angiotensin II (Ang II), c-myc mRNA, and oncoprotein were determined by immunohistochemical method, Northern blot, and Western blot, respectively.
  
  
  RESULTS
  Cap reduced SBP, LVW/BW in SHR, with a decrease of Ang II and c-myc expression in LV. Local cardial Ang II mainly distributed in cardiomyocytes. Cap inhibited cardial Ang II production and c-myc expression (histochemical staining intensity index, 0.49 +/- 0.04 vs 0.83 +/- 0.24, P < 0.01). The c-myc oncoprotein was prevailingly located in cardiac fibroblasts. The c-myc oncoprotein in Cap treated SHR was lower than that of WKY.
  
  
  CONCLUSIONS
  High expression of c-myc in fibroblasts played an important role in the development of LVH in SHR. Inhibitory effects of Cap on LVH was associated with a decreased myocardial Ang II and interstitial fibroblasts c-myc expression. The c-myc oncoprotein post-transcriptional translation was also interrupted by Cap.
authors.affiliation: Department of Cardiology, First Affiliated Hospital of Fujian Medical University, Fujian Institute of Hypertension, Fuzhou, China. sujinzi@163.net
authors.forename: J Z
authors.initials: JZ
authors.lastname: Su
authors.forename: D G
authors.initials: DG
authors.lastname: Chen
authors.forename: K G
authors.initials: KG
authors.lastname: Wu
authors.forename: S C
authors.initials: SC
authors.lastname: Chen
authors.forename: W Y
authors.initials: WY
authors.lastname: Hu
authors.forename: X Y
authors.initials: XY
authors.lastname: Wang
authors.forename: H B
authors.initials: HB
authors.lastname: Rui
authors.forename: H J
authors.initials: HJ
authors.lastname: Wang
authors.forename: C S
authors.initials: CS
authors.lastname: Xu
mesh_terms: D000804:Angiotensin II / Q000378:metabolism; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D002216:Captopril / Q000494:pharmacology*; D016259:Genes, myc; D006973:Hypertension / Q000235:genetics / Q000378:metabolism; D017379:Hypertrophy, Left Ventricular / Q000235:genetics / Q000378:metabolism*; D008297:Male; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D000804:Angiotensin II; D002216:Captopril